News Releaseshttp://www.asiamerlion.cn/News Releasesenhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-continues-to-advance-growth-strategy-with-sale-of-non-core-assets-in-latin-america/http://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-continues-to-advance-growth-strategy-with-sale-of-non-core-assets-in-latin-america/ Takeda Continues to Advance Growth Strategy with Sale Of Non-Core Assets in Latin AmericaThu, 16 Sep 2021 18:00:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-exkivity-mobocertinib-approved-by-us-fda/http://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-exkivity-mobocertinib-approved-by-us-fda/ Takeda’s EXKIVITY? (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLCWed, 15 Sep 2021 04:00:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-to-manufacture-and-provide-150-million-doses-of-novavax-covid-19-vaccine-candidate-to-the-government-of-japan/http://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-to-manufacture-and-provide-150-million-doses-of-novavax-covid-19-vaccine-candidate-to-the-government-of-japan/ Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of JapanTue, 07 Sep 2021 01:35:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-provides-update-on-phase-3-panther-pevonedistat-3001-trial/http://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-provides-update-on-phase-3-panther-pevonedistat-3001-trial/ Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) TrialWed, 01 Sep 2021 20:30:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-updates-its-q1-fy2021-earnings-materials-to-reflect-impact-of-decision-by-the-irish-tax-appeals-commission-relating-to-tax-assessment-on-break-fee-shire-received-from-abbvie/http://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-updates-its-q1-fy2021-earnings-materials-to-reflect-impact-of-decision-by-the-irish-tax-appeals-commission-relating-to-tax-assessment-on-break-fee-shire-received-from-abbvie/ Takeda Updates its Q1 FY2021 Earnings Materials to Reflect Impact of Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVieFri, 06 Aug 2021 06:00:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/final-results-from-the-longest-hereditary-angioedema-study/http://www.asiamerlion.cn/newsroom/newsreleases/2021/final-results-from-the-longest-hereditary-angioedema-study/ Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO? (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema AttacksThu, 05 Aug 2021 11:00:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-receives-decision-by-the-irish-tax-appeals-commission-relating-to-tax-assessment-on-break-fee-shire-received-from-abbvie/http://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-receives-decision-by-the-irish-tax-appeals-commission-relating-to-tax-assessment-on-break-fee-shire-received-from-abbvie/ Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVieSun, 01 Aug 2021 23:30:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-delivers-solid-first-quarter-fy2021-results-positioning-company-to-accelerate-topline-growth-and-continued-pipeline-progress/http://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-delivers-solid-first-quarter-fy2021-results-positioning-company-to-accelerate-topline-growth-and-continued-pipeline-progress/ Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline ProgressFri, 30 Jul 2021 06:00:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-and-frazier-healthcare-partners-announce-collaboration--to-launch-hillevax-inc.-to-develop-clinical-stage-norovirus-vaccine-candidate/http://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-and-frazier-healthcare-partners-announce-collaboration--to-launch-hillevax-inc.-to-develop-clinical-stage-norovirus-vaccine-candidate/ Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine CandidateThu, 29 Jul 2021 14:00:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/us-food-and-drug-administration-grants-breakthrough-therapy-designation-to-takedas-investigational-compound-tak-994/http://www.asiamerlion.cn/newsroom/newsreleases/2021/us-food-and-drug-administration-grants-breakthrough-therapy-designation-to-takedas-investigational-compound-tak-994/ U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)Wed, 28 Jul 2021 15:00:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-to-hold-first-quarter-fy2021-earnings-conference-calls/http://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-to-hold-first-quarter-fy2021-earnings-conference-calls/ Takeda to Hold First Quarter FY2021 Earnings Conference CallsMon, 26 Jul 2021 10:00:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-data-at-isth-2021-highlight-the-benefits-of-prophylaxis-for-patients-with-rare-bleeding-disorders/http://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-data-at-isth-2021-highlight-the-benefits-of-prophylaxis-for-patients-with-rare-bleeding-disorders/ Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding DisordersTue, 20 Jul 2021 19:00:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-expands-modernas-covid-19-vaccine-supply-in-japan-in-partnership-with-the-japanese-government/http://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-expands-modernas-covid-19-vaccine-supply-in-japan-in-partnership-with-the-japanese-government/ Takeda Expands Moderna’s COVID-19 Vaccine Supply in Japan in Partnership with the Japanese GovernmentTue, 20 Jul 2021 08:30:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-announces-the-submission-of-its-corporate-governance-report-to-the-tokyo-stock-exchange/http://www.asiamerlion.cn/newsroom/newsreleases/2021/takeda-announces-the-submission-of-its-corporate-governance-report-to-the-tokyo-stock-exchange/ Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock ExchangeMon, 19 Jul 2021 10:30:00 Zhttp://www.asiamerlion.cn/newsroom/newsreleases/2021/new-data-from-the-phase-3-help-study-open-label-extension-evaluating-safety-and-efficacy-of-takhzyro/http://www.asiamerlion.cn/newsroom/newsreleases/2021/new-data-from-the-phase-3-help-study-open-label-extension-evaluating-safety-and-efficacy-of-takhzyro/ New Data from the Phase 3 HELP Study??Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO??(lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid CongressFri, 09 Jul 2021 22:00:00 Z国产AV网站_中午文字幕av一区二区三区_性进入裸体视频_久久久久久精品免费免费直播